Mar 29, 2017 12:07 pm UTC| Business
-- Data suggest high prevalence of CRE with rapid rate of increase -- -- Company’s late-stage candidate, plazomicin, may provide an important new option in treating MDR infections, including those caused by CRE -- ...
Mar 29, 2017 12:07 pm UTC| Business
-- Data suggest high prevalence of CRE with rapid rate of increase -- -- Company’s late-stage candidate, plazomicin, may provide an important new option in treating MDR infections, including those caused by CRE -- ...
Mar 29, 2017 12:07 pm UTC| Business
-- Data suggest high prevalence of CRE with rapid rate of increase -- -- Company’s late-stage candidate, plazomicin, may provide an important new option in treating MDR infections, including those caused by CRE -- ...
Mar 29, 2017 12:07 pm UTC| Business
-- Data suggest high prevalence of CRE with rapid rate of increase -- -- Company’s late-stage candidate, plazomicin, may provide an important new option in treating MDR infections, including those caused by CRE -- ...
Mar 29, 2017 12:07 pm UTC| Business
-- Data suggest high prevalence of CRE with rapid rate of increase -- -- Company’s late-stage candidate, plazomicin, may provide an important new option in treating MDR infections, including those caused by CRE -- ...
Mar 29, 2017 12:07 pm UTC| Business
-- Data suggest high prevalence of CRE with rapid rate of increase -- -- Company’s late-stage candidate, plazomicin, may provide an important new option in treating MDR infections, including those caused by CRE -- ...
Auris Medical to Present at the 16th Annual Needham Healthcare Conference on April 5
Mar 29, 2017 12:07 pm UTC| Business
ZUG, Switzerland, March 29, 2017 - Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology, today announced that...